^
Association details:
| Biomarker: | CYP17A1 V366M |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency
Excerpt:
The V366M mutant also explained the effectiveness of the anti-prostate cancer drug abiraterone as a potent inhibitor of CYP17A1 by binding tightly at the active site in the WT enzyme.
DOI:
10.3390/ph11020037
